Multiplikator forward rega marang pendapatan: Actuate Therapeutics Inc. (ACTU)

The market trend for Actuate Therapeutics, Inc. (ACTU) is driven by extreme regulatory threats during the early stages of clinical trials. Analyzing the company's expected P/S chart on GURU.Markets, we see that represents the final metric reading. Growth potential is based on the launch of eladrasib for glioblastoma therapy; however, the lack of revenue and reliance on speculative capital create significant risks for investors.
Rincian analitis perusahaan Actuate Therapeutics, Inc. (ACTU)

The margin of safety assessment for Actuate Therapeutics, Inc. (ACTU) is based on the ratio of market value to expected annual sales, which currently stands at . By analyzing the forward P/S indicator, an investor determines the degree of overvaluation of the capitalization relative to revenue forecasts, which is critically important for a biopharmaceutical company developing innovative GSK-3 beta inhibitors to combat resistant forms of metastatic cancer.